GLPwatch
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.
JAMA · 2026
Last updated 2026-07-12| Journal | JAMA, 2026 |
|---|---|
| Citations | 0 |
| Molecules | mazdutide |
Full record and abstract on PubMed 42251596 ↗
Related research
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.
- Mazdutide versus placebo in Chinese adults with type 2 diabetes.
- Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.